New scan could spot hidden prostate cancer

NCT ID NCT03181867

Ongoing Diagnosis Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after treatment. The goal is to improve staging and detection of recurrence, guiding better treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-DCFPyL (a radioactive tracer for PET/CT scans)
What this could lead to: If successful, this could provide a more accurate way to detect where prostate cancer has spread or returned, helping doctors choose the right treatment.
What could go wrong: This is a phase 2 study, so it is still early. The tracer may not prove more effective than current imaging, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate carcinoma prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF PROSTATE METASTATIC PROSTATE CANCER PROSTATE CANCER PROSTATE NEOPLASMS PROSTATIC CANCER

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.